MSKCC to Seek CDx Status From FDA for Markers on Cancer NGS Panel

WASHINGTON, DC (GenomeWeb) – Memorial Sloan Kettering Cancer Center is pursuing national Medicare coverage for its MSK-IMPACT next-generation sequencing cancer profiling test by filing with the US Food and Drug Administration to garner companion diagnostic status for at least one marker on the multi-gene panel.

Get the full story with
GenomeWeb Premium Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Be the first to comment

Leave a Reply

Your email address will not be published.


*